Medexus Pharmaceuticals Schedules Second Quarter Fiscal 2020 Conference Call
November 25 2019 - 9:22AM
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”)
(TSXV: MDP, OTCQB: PDDPF) today announced that it plans to
host a conference call at 8:00 AM Eastern Time on Monday, December
2, 2019 to discuss the Company’s financial results for the second
quarter ended September 30, 2019, as well as the Company’s
corporate progress and other developments. The Company expects
to file its financial statements along with its MD&A post
market on November 29, 2019.
The conference call will be available via
telephone by dialing toll free 844-369-8770 for Canadian and U.S.
callers or +1 862-298-0840 for international callers, or on the
Company’s Investor Events section of the
website: https://www.medexus.com/news-media/events.
A webcast replay will be available on the
Company’s Investor Events section of the website
(https://www.medexus.com/news-media/events) through March 2, 2020.
A telephone replay of the call will be available approximately one
hour following the call, through December 9, 2019, and can be
accessed by dialing 877-481-4010 for Canadian and U.S. callers or
+1 919-882-2331 for international callers and entering conference
ID: 56859.
About Medexus Pharmaceuticals
Inc.
Medexus is a leading specialty pharmaceutical
company with a strong North American commercial platform. The
Company’s vision is to provide the best healthcare products to
healthcare professionals and patients, through our core values of
Quality, Innovation, Customer Service and Teamwork. Medexus
Pharmaceuticals is focused on the therapeutic areas of auto-immune
disease and pediatrics. The leading products are Rasuvo and
Metoject, a unique formulation of methotrexate (auto-pen and
pre-filled syringe) designed to treat rheumatoid arthritis and
other auto-immune diseases; and Rupall, an innovative allergy
medication with a unique mode of action.
For more information, please
contact:
Ken d’Entremont, Chief Executive OfficerMedexus
Pharmaceuticals Inc.Tel.: 905-676-0003E-mail:
ken.dentremont@medexus.com
Roland Boivin, Chief Financial OfficerMedexus
Pharmaceuticals Inc.Tel.: 514-762-2626 ext. 202E-mail:
roland.boivin@medexus.com
Investor Relations
(U.S.):Crescendo Communications, LLCTel:
+1-212-671-1020Email: mdp@crescendo-ir.com
Investor Relations
(Canada):Frank CandidoDirect Financial Strategies
and Communication Inc.Tel: 514-969-5530E-mail:
frank.candido@medexus.com
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Medexus Pharmaceuticals (TSXV:MDP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Medexus Pharmaceuticals (TSXV:MDP)
Historical Stock Chart
From Jul 2023 to Jul 2024